By Erin Kennedy – Updated Nov 18, 2026 at 7:11AM EST.

10 stocks we like better than CME Group ›.

Industry observers note that investors today can choose between the massive cash generation of a global financial exchange and the high-growth disruption of an AI lending platform. Is CME Group (CME -0.46%) or Upstart (UPST +1.10%) the better buy?

CME Group provides the critical infrastructure for global risk management, while Upstart uses advanced technology to redefine personal credit. While both companies operate within the financial services sector, they offer very different risk and reward profiles. Comparing their recent performance and valuation can help you decide which stock fits your 2027 goals.

In its latest annual report, filed for the fiscal year ended Dec. 31, 2025, CME Group describes its position as the world's leading derivatives marketplace. The manufacturer provides essential trading and clearing services across major asset classes. Key partnerships include a strategic 10-year cloud infrastructure deal with Alphabet (GOOGL +1.62%) (GOOG +1.06%) and a prediction markets joint venture with Flutter Entertainment (FLUT -0.28%). In 2025, one clearing firm accounted for nearly 12% of total clearing and transaction fees. Customer concentration like this adds a layer of risk to the business.

In a recent development, reliable recent quarterly figures for at least one of these companies aren't available, so this comparison uses each organization's latest full fiscal year. In the fiscal year ended Dec. 31, 2025, revenue reached nearly $6.5 billion, representing 6.4% growth over the previous fiscal year. Net income for the period was close to $4 billion. This high level of profitability stems from the company's vital role in global financial markets.

As of CME's December 2025 balance sheet, the debt-to-equity ratio was approximately 0.1. This low ratio shows that total debt is only a small fraction of shareholder equity. The current ratio of roughly 1 measures the ability to cover short-term debts with short-term assets. Free cash flow was approximately $4.2 billion in fiscal 2025. This metric represents the cash remaining after a business covers its operating expenses and capital expenditures.

Industry observers note that upstart operates an AI-powered lending marketplace that aims to modernize traditional credit scoring. The tech giant connects individual borrowers with more than 100 bank and credit union partners. Its business relies on high-traffic aggregators like Credit Karma to attract new applicants to the platform. This ecosystem currently places the company among the most innovative fintech stocks in the market today.

In the fiscal year ended Dec. 31, 2025, Upstart reported revenue of approximately $1 billion. This represented a substantial 64% increase compared to the prior 12-month period. The firm also returned to profitability, reporting net income of nearly $53.6 million. This turnaround highlights the potential scalability of its AI-driven lending model.

In a recent development, as of its December 2025 balance sheet, the debt-to-equity ratio was roughly 2.3. This means total liabilities are more than double the organization's shareholder equity. The current ratio was approximately 3, indicating the company has three times more short-term assets than short-term liabilities. Free cash flow for the period was negative $166.1 million.

CME Group faces risks from global market volatility and fluctuations in trading volumes. Its reliance on technology infrastructure makes it susceptible to cybersecurity threats, such as the cooling failure at a CyrusOne data center in late 2025. The organization also deals with intense competition from rivals like Intercontinental Exchange (ICE -0.12%) and Cboe Global Markets (CBOE -0.95%). Licensing agreements with benchmark providers such as S&P Global (SPGI -0.36%) also present ongoing intellectual property risks.

In a recent development, upstart is highly dependent on a limited number of lending partners and institutional investors for loan funding. The firm also carries risks if its proprietary AI models contain errors or fail to account for changing macroeconomic conditions. Furthermore, it is presently involved in securities class action lawsuits alleging misrepresentation of its model's effectiveness. Regulatory scrutiny over fair lending compliance and the bank partnership model remains a persistent concern for the business.

CME Group currently trades at a lower forward P/E than Upstart, which suggests it is priced more conservatively relative to future earnings estimates.

Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.

These two companies are in very different stages of the business life cycle. CME Group is a mature, established organization, with roots dating back to the 19th century. Upstart, meanwhile, was founded in 2012 and only went public in late 2020. The derivatives specialist also boasts a strong 60%-plus net margin, while Upstart is only barely profitable.

Sources indicate that upstart's stock has been a disappointment since its public debut. Indeed, it's hovering near 52-week lows. That said, CME Group has lagged the market (though not as badly), trailing the S&P 500 (^GSPC +0.33%) by more than 20 percentage points.

According to recent reports, these stocks, I think, fundamentally appeal to very different investors. Those interested in innovative companies with skyrocketing revenue and growth potential would probably pick Upstart. Investors who prefer strong margins paired with a modest dividend would likely opt for CME Group. I'm in the latter camp: CME gets my vote for 2027 and beyond.

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 802%* — a market-crushing outperformance compared to 205% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

*Stock Advisor returns as of November 18, 2026.

→ Read original article